Sistema de Salut de Catalunya
Institut Català de la Salut
[Oscanoa TJ] Universidad Nacional Mayor de San Marcos. Facultad de Medicina, Lima, Perú. Universidad de San Martín de Porres. Facultad de Medicina Humana. Drug Safety Research Center, Lima, Perú. Servicio de Geriatría del Hospital Almenara, ESSALUD, Lima, Peru. [Vidal X] Servei de Farmacologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Luque J] Universidad de San Martín de Porres. Facultad de Medicina Humana. Drug Safety Research Center, Lima, Perú. [Julca DI] Universidad Nacional Mayor de San Marcos. Facultad de Medicina, Lima, Perú. [Romero-Ortuno R] Discipline of Medical Gerontology, Mercer’s Institute for Successful Ageing, St James’s Hospital, Dublin, Ireland. Global Brain Health Institute, Trinity College Dublin, Ireland
Vall d'Hebron Barcelona Hospital Campus
2023-05-04T10:21:49Z
2023-05-04T10:21:49Z
2023
Adverse drug reaction; Latent tuberculosis; Liver injury
Reacción adversa a medicamentos; Tuberculosis latente; Lesión hepática
Reacció adversa a medicaments; Tuberculosi latent; Lesió hepàtica
Aim: The aim of the present study was to conduct a meta-analysis of the frequency of isoniazid-induced liver injury (INH-ILI) in patients receiving isoniazid (INH) preventative therapy (IPT). Background: The frequency of hepatotoxicity (drug-induced liver injury: DILI) of antituberculosis drugs has been studied, especially when INH, rifampin, and pyrazinamide are co-administered. However, little is known about the frequency of DILI in patients with latent tuberculosis infection (LTBI), where IPT is indicated. Methods: We searched PubMed, Google Scholar, and the Cochrane Database of Systematic Reviews for studies reporting the frequency of INH-ILI in patients with IPT using one or more diagnostic indicators included in the criteria of the DILI Expert Working Group. Results: Thirty-five studies comprising a total of 22,193 participants were included. The overall average frequency of INH-ILI was 2.6% (95% CI, 1.7-3.7%). The mortality associated with INH-DILI was 0.02% (4/22193). Subgroup analysis revealed no significant differences in the frequency of INH-ILI in patients older or younger than 50 years, children, patients with HIV, candidates for liver, kidney, or lung transplant, or according to the type of study design. Conclusion: The frequency of INH-ILI in patients receiving IPT is low. Studies on INH-ILI are needed where the current DILI criteria are used.
Article
Published version
English
Tuberculosi; Medicaments antituberculosos - Efectes secundaris; Hepatotoxicitat; DISEASES::Chemically-Induced Disorders::Chemically-Induced Disorders::Poisoning::Chemical and Drug Induced Liver Injury; DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Actinomycetales Infections::Mycobacterium Infections::Tuberculosis::Latent Tuberculosis; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents::Antitubercular Agents; ENFERMEDADES::trastornos inducidos químicamente::trastornos inducidos químicamente::intoxicación::trastornos hepáticos provocados por fármacos y productos químicos; ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones por Actinomycetales::micobacteriosis::tuberculosis::tuberculosis latente; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos::antituberculosos
Research Institute for Gastroenterology and Liver Diseases
Gastroenterology and Hepatology from Bed to Bench;16(1)
https://doi.org/10.22037/ghfbb.v16i1.2685
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3440]
